Neurotoxicity during ifosfamide treatment in children

Medical Science Monitor

Volumn 15, Issue 1, 2009, Pages

  Di Cataldo, Andrea ^a   Astuto, Marinella ^a   Rizzo, Giuliana ^a   Bertuna, Gregoria ^a   Russo, Giovanna ^a   Incorpora, Gemma ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Child; Ifosfamide; Neurotoxicity; Tumor

Indexed keywords

ALBUMIN; CHLORIDE; CREATININE; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DEXAMETHASONE; DIAZEPAM; DOXORUBICIN; ETOPOSIDE; GLUCOSE; IFOSFAMIDE; MESNA; METHOTREXATE; METHYLENE BLUE; PHOSPHATE; SODIUM; THIAMINE; VINCRISTINE;

ABDOMINAL MASS; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALBUMIN BLOOD LEVEL; ANEMIA; APHASIA; ARTICLE; BRAIN DISEASE; BRAIN METASTASIS; BURKITT LYMPHOMA; CANCER SURGERY; CASE REPORT; CHILD; CHLORIDE BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; CYANOSIS; DIZZINESS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSARTHRIA; ELECTROENCEPHALOGRAM; ELECTROLYTE BLOOD LEVEL; EWING SARCOMA; FEMALE; FLAPPING TREMOR; GLUCOSE BLOOD LEVEL; GRAND MAL SEIZURE; HEADACHE; HUMAN; HUMAN TISSUE; IRRITABILITY; KARNOFSKY PERFORMANCE STATUS; KIDNEY TUBULE DISORDER; LEUKEMIA; LEUKOCYTOSIS; LUNG BLASTOMA; LYMPH NODE; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE HYPERTONIA; MUSCLE HYPOTONIA; NEUROBLASTOMA; NEUROLOGIC EXAMINATION; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE; OPHTHALMOSCOPY; PHOSPHATE BLOOD LEVEL; PLEURA EFFUSION; REMISSION; RESPIRATORY DISTRESS; RESPIRATORY FUNCTION DISORDER; RISK FACTOR; SIDE EFFECT; SODIUM BLOOD LEVEL; SOLID TUMOR; SOMNOLENCE; TACHYCARDIA; THROMBOCYTOPENIA; TUMOR BIOPSY; URINALYSIS; VOMITING;

ADOLESCENT; ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IFOSFAMIDE; MALE; NEOPLASMS; NEUROTOXICITY SYNDROMES;

EID: 58649113207     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Voute PA, Van den Berg H, Behrendt H et al: Ifosfamide in the treatment of pediatric malignancies. Semin Oncol, 1996; 23(Suppl.7): 8-11
2. Antman KH, Elias A, Ryan L: Ifosfamide and mesna: response and toxicity at standard and high dose schedules. Semin Oncol, 1990; 1: 68-73
3. Pratt CB, Green AA, Horowitz ME et al: Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol, 1986; 4: 1253-61
4. Shuper A, Stein J, Goshen J et al: Subacute central nervous system degeneration in a child: an unusual manifestation of ifosfamide intoxication. J Child Neurol, 2000; 15: 481-83
5. Ajithkumar T, Parkinson C, Shamshad F, Murray P: Ifosfamide encephalopathy. Clin Oncol (R Coll Radiol), 2007; 19: 108-14
6. Dufour C, Grill J, Sabouraud P et al: Ifosfamide induced encephalopathy: 15 observations. Arch Pediatr, 2006; 13: 140-45
7. Bruggers CS, Friedman HS, Tien R, Delong R: Cerebral atrophy in an infant following treatment with ifosfamide. Med Pediatr Oncol, 1994; 23: 380-83
8. Bhardwaj A, Badesha PS: Ifosfamide-induced nonconvulsive status epilepticus. Ann Pharmacother, 1995; 29: 1237-39
9. Anderson N, Tandon DS: Ifosfamide extrapyramidal neurotoxicity. Cancer, 1991; 68: 72-75
10. Cameron JC: Ifosfamide neurotoxicity a challenge for nurses, a potential nightmare for patients. Cancer Nurs, 1993; 16: 40-46
11. Kupfer A, Aeschlimann C, Cedny T: Methylene blue and the neurotoxic mechanism of ifosfamide encephalopathy. Eur J Clin Pharmacol, 1996; 50: 249-52
12. Pelgrims J, De Vos F, Van den Brande J et al: Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer, 2000; 82: 291-94
13. Hamadani M, Awan F: Role of thiamine in managing ifosfamide-induced encephalopathy. J Oncol Pharm Practice, 2006; 12: 237-39
14. De Bernardi B, Nicolas B, Boni L et al: Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian co-operative group for neuroblastoma. J Clin Oncol, 2003; 21: 1592-601
15. David KA, Picus J: Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol, 2005; 28: 277-80
16. Posner JB: Paraneoplastic Syndromes: Curr Opin Neurol, 1997; 10: 471-76
17. Di Cataldo A, Palumbo M, Pittalà D et al: Deletions in mitochondrial DNA and decrease in the oxidative phosphorylation activity of children with Fanconi syndrome secondary to antiblastic therapy. Am J Kidney Dis, 1999; 34: 98-106
18. Buesa JM, Garcia-Teijido P, Losa R, Fra J: Treatment of ifosfamide encephalopathy with intravenous thiamine. Clin Cancer Res, 2003; 9(12): 4636-37